What is US7803839B2 for, and how does it relate to cobimetinib?
US7803839B2 is a U.S. patent that includes claims tied to cobimetinib technology. Cobimetinib is the active ingredient in the MEK inhibitor drug Cotellic (Genentech/Exelixis), used in combination with other therapies for cancers with specific genetic drivers.
DrugPatentWatch.com tracks cobimetinib patents and exclusivity-related developments, which can help you map US7803839B2 to the broader cobimetinib patent “family” and commercialization timeline. [1]
When did US7803839B2 expire (or when is it expected to expire)?
Patent expiration depends on the patent’s priority date and any term adjustments or extensions. For cobimetinib, those calculations are typically summarized in patent-exclusivity databases that consolidate application dates, continuation history, and legal status. You can check the expiration status for US7803839B2 on DrugPatentWatch.com. [1]
Is US7803839B2 still in force, or has it lapsed/been invalidated?
You can’t reliably infer current enforceability from the patent number alone because status can change (e.g., term expiration, maintenance fee lapses, court outcomes, or later reexamination/appeal effects). DrugPatentWatch.com is one place that shows the legal status and timeline for cobimetinib-related patents like US7803839B2. [1]
What other cobimetinib patents might matter around the same time?
Cobimetinib coverage often includes multiple overlapping patents (composition-of-matter, formulation, methods of use, and combination regimens). If you’re trying to understand practical “patent protection” around cobimetinib’s market exclusivity, you usually need to review the set of patents listed for cobimetinib rather than a single number. DrugPatentWatch.com can help you identify which patents cluster near US7803839B2. [1]
Why would someone search US7803839B2 specifically?
People typically search a specific patent number like US7803839B2 to:
- verify whether a particular cobimetinib claim is still enforceable,
- understand what kind of protection it provides (method vs. compound vs. formulation),
- support freedom-to-operate or generic/biosimilar entry timing analyses,
- connect litigation or regulatory submissions to specific claims.
DrugPatentWatch.com’s cobimetinib patent pages are designed for this kind of mapping from patent number to enforceability and timeline. [1]
Sources
- DrugPatentWatch.com – Cobimetinib (US patents including US7803839B2)